conference reports
7th ESOU Meeting: key messages, renal cancer session
Tuesday, 19 January 2010- Key treatment issues, complications and emerging diagnostic and surgical techniques in renal cancer were discussed in the recent 7th Meeting of the EAU Section of Oncological Urology (ESOU)...
By Joel Vega
Compariing pazopanib’s efficacy in cytokine pretreated patients with advanced RCC
Wednesday, 30 December 2009- Pazopanib, an oral multikinase angiogenesis inhibitor, has shown clinical efficacy in patients with advanced RCC. In a study (VEG105192) by C. Sternberg and colleagues, the efficacy and safety of...
Edited by: Joel Vega
More medical options for mRCC but progress needed to reduce toxicities, identify biomarkers
Thursday, 10 December 2009- More medical treatment options are available to patients with metastatic renal cell carcinoma (mRCC), but more progress is needed particularly in terms of boosting the safety or reducing the...
By Joel Vega
Bladder cancer and RCC: from diagnosis to follow-up
Wednesday, 2 December 2009 - Various aspects related to the diagnosis, prognosis and treatment of bladder cancer were dealt with in the framework of several sections of the 2nd Multidisciplinary Meeting on Urological Cancers held...
By Evgenia Starkova
Effects of prolonged warm and cold ischemia in an experimental solitary kidney model
Monday, 12 October 2009- A group of researchers in Greece assessed the effects of prolonged warm and cold ischemia of an animal model with a solitary kidney undergoing partial nephrectomy at the ultrastructural level,...
Edited by: Joel Vega
VEGF inhibitor Axitinib shows promise in refractory RCC
Wednesday, 7 October 2009- A selective angiogenesis inhibitor achieved stable disease or better response in 95% of patients with treatment-refractory metastatic renal cell cancer (mRCC) in a small phase II Japanese study reported...
Edited by: JV
Targeted therapy combination active in pre-treated mRCC
Friday, 2 October 2009- A combination of targeted therapies demonstrated clinical activity in a majority of patients with previously treated metastatic renal cell carcinoma (mRCC), according to a small study reported during the...
Edited by: JV
Scientists say multidisciplinary treatment of mRCC has potential
Wednesday, 29 July 2009- Multidisciplinary approach to the treatment of mRCC may lengthen the tumour-dependant survival time, according to the results of a new study, conducted by a group of researchers from Poland.
The results...
Edited by: ES
Cost-effectiveness of zoledronic acid in preventing SREs in mRCC patients with bone mets
Thursday, 9 July 2009- Zoledronic acid (ZOL) significantly reduces the risk of new skeletal-related events (SREs) in patients (pts) with bone metastases from renal cell carcinoma (RCC).
Multi-centre investigators assessed and...
Edited by: JV
Prognostic factors for overall survival in mRCC patients treated with VEGF agents
Friday, 3 July 2009- Prognostic factors (PF) for overall survival (OS) have yet to be fully defined for patients with metastatic RCC in the era of VEGF-targeted therapy. A multi-centre study conducted by researchers in US and...
Edited by: JV
